Global Information
회사소개 | 문의 | 비교리스트

급성 폐손상 : 파이프라인 리뷰

Acute Lung Injury - Pipeline Review, H2 2016

리서치사 Global Markets Direct
발행일 2016년 12월 상품 코드 229781
페이지 정보 영문 97 Pages
가격
US $ 2,000 ₩ 2,417,000 PDF by E-mail (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 4,000 ₩ 4,834,000 PDF by E-mail (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 6,000 ₩ 7,251,000 PDF by E-mail (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


급성 폐손상 : 파이프라인 리뷰 Acute Lung Injury - Pipeline Review, H2 2016
발행일 : 2016년 12월 페이지 정보 : 영문 97 Pages

급성 폐손상(ALI)이란 좌심방 고혈압이 원인이 아닌 급성·중증 산소 결핍 증상이라는 특징을 가진 일반 질환입니다. ALI는 전신성 염증, 특히 전신성 패혈증에서 가장 많이 볼 수 있는 증상으로, 폐에서도 다른 조직에서도 같은 증상이 나타납니다. ALI의 주요 병인은 패혈증이나 화상, 방사선, 유해가스 흡입, 지방색전증 등입니다. 주요 증상은 극도의 헐떡임, 저혈압, 의식 혼탁, 극도의 권태감 등입니다.

세계 각국에서의 급성 폐손상(ALI: Acute Lung Injury) 치료용 파이프라인 제품 개발 상황에 대해 분석했으며, 제품 개발 및 출시 최신 동향, 임상시험 각 단계 제품 목록, 주요 기업 개요, 주요 약제 개요, 최신 업계 동향 등의 정보를 전해드립니다.

목차

서론

  • 분석 범위

급성 폐손상 개요

치료제 개발

  • 급성 폐손상용 파이프라인 제품 : 개요
  • 급성 폐손상용 파이프라인 제품 : 비교 분석

각 기업에서 개발중인 급성 폐손상 치료제

대학/연구기관에서 연구중인 급성 폐손상 치료제

파이프라인 제품 개요

  • 임상시험 단계 제품
  • 초기 단계 제품

급성 폐손상 치료제 : 개발중인 제품 목록(기업별)

급성 폐손상 치료제 : 연구중인 제품 목록(대학/연구기관별)

급성 폐손상 치료제 개발에 참여하고 있는 기업

  • Altor BioScience Corporation
  • Apeptico Forschung und Entwicklung GmbH
  • Commence Bio, Inc.
  • CompleGen, Inc.
  • FirstString Research, Inc.
  • GlaxoSmithKline Plc
  • Histocell S.L.
  • Navigen Pharmaceuticals, Inc.
  • Noxxon Pharma AG
  • Quark Pharmaceuticals, Inc.
  • S-Evans Biosciences, Inc.
  • Silence Therapeutics Plc
  • Stemedica Cell Technologies, Inc.
  • Windtree Therapeutics, Inc.

급성 폐손상 : 치료제 평가

  • 단독치료 제품(Monotherapy Products)별
  • 표적별
  • 작용기전별
  • 투여 방법별
  • 분자 종류별

약제 개요

급성 폐손상 치료제 : 휴지 상태인 프로젝트

급성 폐손상 치료제 : 개발이 중지된 제품

급성 폐손상 관련 제품 개발 마일스톤

  • 주목해야 할 최신 동향과 프레스 릴리스

부록

도표

LSH 16.09.30

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Acute Lung Injury - Pipeline Review, H2 2016, provides an overview of the Acute Lung Injury (Respiratory) pipeline landscape.

Acute lung injury (ALI) is a common condition that is characterized by acute severe hypoxia that is not due to left atrial hypertension. ALI is most often seen as part of a systemic inflammatory process, particularly systemic sepsis, where the lung manifestations parallel those of other tissues. Causes of ALI include sepsis, burns, radiation, inhalation of noxious fumes and fat embolism. Symptoms include severe shortness of breath, low blood pressure, confusion and extreme tiredness

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Acute Lung Injury - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Acute Lung Injury (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Acute Lung Injury (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Acute Lung Injury and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 4, 1, 19 and 2 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 8 and 3 molecules, respectively.

Acute Lung Injury (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Acute Lung Injury (Respiratory).
  • The pipeline guide reviews pipeline therapeutics for Acute Lung Injury (Respiratory) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Acute Lung Injury (Respiratory) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Acute Lung Injury (Respiratory) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Acute Lung Injury (Respiratory)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Acute Lung Injury (Respiratory).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Acute Lung Injury (Respiratory) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Acute Lung Injury Overview
  • Therapeutics Development
    • Pipeline Products for Acute Lung Injury - Overview
    • Pipeline Products for Acute Lung Injury - Comparative Analysis
  • Acute Lung Injury - Therapeutics under Development by Companies
  • Acute Lung Injury - Therapeutics under Investigation by Universities/Institutes
  • Acute Lung Injury - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Acute Lung Injury - Products under Development by Companies
  • Acute Lung Injury - Products under Investigation by Universities/Institutes
  • Acute Lung Injury - Companies Involved in Therapeutics Development
    • Altor BioScience Corp
    • Asklepion Pharmaceuticals LLC
    • Commence Bio Inc
    • CompleGen Inc
    • GlaxoSmithKline Plc
    • Histocell SL
    • Lung Therapeutics Inc
    • Navigen Pharmaceuticals Inc
    • Quark Pharmaceuticals Inc
    • S-Evans Biosciences Inc
    • Silence Therapeutics Plc
    • Stemedica Cell Technologies Inc
  • Acute Lung Injury - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • ALT-836 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Atu-111 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BC-1215 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BIO-10901 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CGX-1037 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CMB-200 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Drugs to Antagonize IGF-1 Receptor for Acute Lung Injury and Pulmonary Fibrosis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Drugs to Inhibit Adenosine A1 Receptor for Lung Injury and Lung Inflammation - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • EC-18 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • FAB-117HC - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GSK-2586881 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GSK-2862277 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • L-Citrulline - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LTI-02 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MG-53 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibodies to Inhibit uPA for Infectious Disease and Respiratory Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibody 1 to Inhibit Aminoprocalcitonin for Sepsis, SIRS, Acute Lung Injury and Alzheimer's Disease - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibody 2 to Inhibit Aminoprocalcitonin for Sepsis, SIRS, Acute Lung Injury and Alzheimer's Disease - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibody to Inhibit Aminoprocalcitonin for Sepsis, SIRS, Acute Lung Injury and Alzheimer's Disease - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NAV-2729 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Oligonucleotide to Inhibit Endothelin-1 for CVS, Oncology and Respiratory Diseases - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • P- BEFizumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Peptide to Activate PAI-1 for Acute Lung Injury - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • QPLI-2 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • R-10001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • R-107 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • R-901 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • R-911 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Recombinant Protein for Acute Lung Injury, Sepsis and Chronic Inflammation - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Recombinant Proteins for Acute Lung Injury - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • S-1229 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Antagonize TLR4 for Acute Lung Injury and Bacterial Sepsis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Stem Cell Therapy for Acute Lung Injury - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Stem Cell Therapy for Bacterial Sepsis, Cardiovascular Disease, CNS Disorders, Metabolic Disorders, Respiratory Disease and Toxicology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Stem Cell Therapy for Diabetes Mellitus, Acute Liver Failure, Osteoarthritis and Neurodegenerative Diseases - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Stem Cell Therapy for Metabolic, Gastrointestinal, Multiple Organ Failure and Respiratory Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Synthetic Peptides for Respiratory Distress Syndrome and Acute Lung Injury - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TXA-302 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Acute Lung Injury - Dormant Projects
  • Acute Lung Injury - Discontinued Products
  • Acute Lung Injury - Product Development Milestones
    • Featured News & Press Releases
      • Mar 03, 2015: Navigen Announces Phase I NIH SBIR Award to support the Development of ARF6 Inhibitors to Treat Acute Lung Injury/Acute Respiratory Distress
      • Aug 05, 2014: Silence Therapeutics Announces Publication of pre-clinical study data on use of Atu111 RNAi in sepsis
      • Sep 10, 2012: Silence Therapeutics' Proof Of Concept Study In Preclinical Model Shows Survival Benefit With Atu111 In Combination With Antibiotics
      • Dec 19, 2011: Apeiron Biologics Announces Initiation Of Phase IIa Study In Acute Lung Injury Patients
      • May 23, 2011: Altor BioScience Receives $3m SBIR Phase II Competing Renewal Grant From NHLBI
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Acute Lung Injury, H2 2016
  • Number of Products under Development for Acute Lung Injury - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Products under Investigation by Universities/Institutes, H2 2016
  • Acute Lung Injury - Pipeline by Altor BioScience Corp, H2 2016
  • Acute Lung Injury - Pipeline by Asklepion Pharmaceuticals LLC, H2 2016
  • Acute Lung Injury - Pipeline by Commence Bio Inc, H2 2016
  • Acute Lung Injury - Pipeline by CompleGen Inc, H2 2016
  • Acute Lung Injury - Pipeline by GlaxoSmithKline Plc, H2 2016
  • Acute Lung Injury - Pipeline by Histocell SL, H2 2016
  • Acute Lung Injury - Pipeline by Lung Therapeutics Inc, H2 2016
  • Acute Lung Injury - Pipeline by Navigen Pharmaceuticals Inc, H2 2016
  • Acute Lung Injury - Pipeline by Quark Pharmaceuticals Inc, H2 2016
  • Acute Lung Injury - Pipeline by S-Evans Biosciences Inc, H2 2016
  • Acute Lung Injury - Pipeline by Silence Therapeutics Plc, H2 2016
  • Acute Lung Injury - Pipeline by Stemedica Cell Technologies Inc, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Acute Lung Injury - Dormant Projects, H2 2016
  • Acute Lung Injury - Dormant Projects (Contd..1), H2 2016
  • Acute Lung Injury - Dormant Projects (Contd..2), H2 2016
  • Acute Lung Injury - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Acute Lung Injury, H2 2016
  • Number of Products under Development for Acute Lung Injury - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Top 10 Molecule Types, H2 2016
  • Number of Products by Stage and Top 10 Molecule Types, H2 2016
Back to Top
전화 문의
F A Q